VRx 3996

Drug Profile

VRx 3996

Alternative Names: CHR-3996; VRx-3996

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Chroma Therapeutics
  • Developer Chroma Therapeutics; Viracta Therapeutics
  • Class Antineoplastics; Pyrimidines; Quinolines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I Solid tumours
  • Preclinical Gastric cancer; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder
  • Phase Unknown Lymphoma

Most Recent Events

  • 05 Dec 2016 Preclinical trials in Gastric cancer in USA (PO)
  • 05 Dec 2016 Preclinical trials in Nasopharyngeal cancer in USA (PO)
  • 05 Dec 2016 Preclinical trials in Post-transplant lymphoproliferative disorder (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top